CTLA4 and colitis: Additionally, nearly half of all patients treated with the combination of anti-CTLA-4 and anti-PD-L1 antibodies develop colitis [41], and anti-CTLA-4 therapy at a high dosage causes colitis more frequently than low-dose therapy.